Economic considerations in the management of Alzheimer’s disease

References

• CourtneyCFarrellDGrayRAD2000 Collaborative Group2004Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trialLancet36321051515220031
   PubMed Web of Science ®Google Scholar
• [AHA and NAC] Alzheimer’s Association and the National Alliance for Caregiving1999Who cares? Families caring for persons with Alzheimer’s diseaseWashington, DC
   Google Scholar
• [APA] American Psychiatric Association1994Committee on nomenclature and statisticsDiagnostic and statistican manual of mental disordersRevised Fourth EditionWashington DCAPA
   Google Scholar
• AndersenCKLauridsenJAndersenK2003Cost of dementia: impact of disease progression estimated in longitudinal dataScand J Public Health311192512745762
   PubMed Web of Science ®Google Scholar
• BaumgartenMBattistaRInfante-RivardC1997Use of physician services among family caregivers of elderly persons with dementiaJ Clin Epidemiol501265729393382
   PubMed Web of Science ®Google Scholar
• BeachDL1997Family caregiving: the positive impact on adolescent relationshipsGerontologist3723389127979
   PubMed Web of Science ®Google Scholar
• BeckerR1991Therapy of cognitive deficit in Alzheimer’s disease: The cholinergic systemBeckerRGiacobiniECholinergic basis for Alzheimer therapyBoston, MABirhauser
   Google Scholar
• BeeriMSWernerPDavidsonM2002The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patientsInt J Geriatr Psychiatry17403811994927
   PubMed Web of Science ®Google Scholar
• BirksJHarveyR2003Donepezil for dementia due to Alzheimer’s diseaseCochrane Database Syst Rev3CD00119012917900
   PubMedGoogle Scholar
• BlesaR2000Galantamine: therapeutic effects beyond cognitionDement Geriatr Cogn Disord11Suppl 1283410971049
   PubMed Web of Science ®Google Scholar
• BrookmeyerRCorradaMMCurrieroFC2002Survival following a diagnosis of Alzheimer diseaseArch Neurol591764712433264
   PubMed Web of Science ®Google Scholar
• BrookmeyerRGraySKawasC1998Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onsetAm J Public Health881337429736873
   PubMed Web of Science ®Google Scholar
• BucksRSAshworthDLWilcockGK1996Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living ScaleAge Ageing25113208670538
   PubMed Web of Science ®Google Scholar
• BurnsA2000The burden of Alzheimer’s diseaseInt J Neuropsychopharmacol331811343622
   PubMedGoogle Scholar
• CallahanCMHendrieHCTierneyWM1995Documentation and evaluation of cognitive impairment in elderly primary care patientsAnn Intern Med12242297856990
   PubMed Web of Science ®Google Scholar
• [CSHAWG] Canadian Study of Health and Aging Working Group1994Canadian study of health and aging: study methods and prevalence of dementiaCMAJ1508999138131123
   PubMed Web of Science ®Google Scholar
• CaroJJGetsiosDMigliaccio-WalleK2001Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time careNeurology579647111571318
   PubMed Web of Science ®Google Scholar
• CaroJJSalasMWardA2002Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in the NetherlandsDement Geriatr Cogn Disord1484912145455
   PubMed Web of Science ®Google Scholar
• CarrDBGoateAPhilD1997Current concepts in the pathogenesis of Alzheimer’s diseaseAm J Med1033S10S9344401
   PubMedGoogle Scholar
• [CDC and NCCDPHP] Centers for Disease Control and National Center for Chronic Disease Prevention and Health Promotion2000Unrealized prevention opportunities: reducing the health and economic burden of chronic illnessAtlanta, GA, USAUS Department of Health and Human Services, Centers for Disease Control and Prevention
   Google Scholar
• Corey-BloomJAnandJVeachJ1998A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt J Geriatr Psychopharmacol15565
   Google Scholar
• CummingsJLColeG2002Alzheimer diseaseJAMA2872335811988038
   PubMed Web of Science ®Google Scholar
• CummingsJLSchneiderLTariotPN2004Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s diseaseAm J Psychiatry161532814992980
   PubMed Web of Science ®Google Scholar
• DeJongROsterlundOWRoyGW1989Measurement of quality-of-life changes in patients with Alzheimer’s diseaseClin Ther11545542776169
   PubMed Web of Science ®Google Scholar
• DoodyRSStevensJCBeckC2001Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology5611546611342679
   PubMed Web of Science ®Google Scholar
• DunkinJJAnderson-HanleyC1998Dementia caregiver burden: a review of the literature and guidelines for assessment and interventionNeurology51Suppl 1S5360discussion S65–79674763
   PubMed Web of Science ®Google Scholar
• EngelhartMJGeerlingsMIRuitenbergA2002Dietary intake of antioxidants and risk of Alzheimer diseaseJAMA2873223912076218
   PubMed Web of Science ®Google Scholar
• ErnstRHayJ1994The US economic and social costs of Alzheimer’s disease revisitedAm J Public Health84126148059882
   PubMed Web of Science ®Google Scholar
• ErnstRLHayJWFennC1997Cognitive function and the costs of Alzheimer disease. An exploratory studyArch Neurol54687939193203
   PubMed Web of Science ®Google Scholar
• EttnerSL1995The impact of “parent care” on female labor supply decisionsDemography3263807774731
   PubMed Web of Science ®Google Scholar
• EvansDA1990Estimated prevalence of Alzheimer’s disease in the United StatesMilbank Q68267892233632
   PubMed Web of Science ®Google Scholar
• FarlowMRAnandRMessinaJJr2000A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s diseaseEur Neurol442364111096224
   PubMed Web of Science ®Google Scholar
• FarlowMRHakeAMessinaJ2001Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progressionArch Neurol584172211255445
   PubMed Web of Science ®Google Scholar
• FarrerLACupplesLAHainesJL1997Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis ConsortiumJAMA2781349569343467
   PubMed Web of Science ®Google Scholar
• FeldmanHGauthierSHeckerJ2003Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burdenJ Am Geriatr Soc517374412757558
   PubMed Web of Science ®Google Scholar
• FeldmanHGauthierSHeckerJ2004Economic evaluation of donepezil in moderate to severe Alzheimer diseaseNeurology636445015326236
   PubMed Web of Science ®Google Scholar
• FeldmanHGauthierSHeckerJ2001A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s diseaseNeurology576132011524468
   PubMed Web of Science ®Google Scholar
• FillitHM1999Improving the quality of managed care for patients with mild to moderate Alzheimer’s diseaseDrug Benefit Trends1611
   Google Scholar
• FillitHMGuttermanEMLewisB1999Donepezil use in managed Medicare: effect on health care costs and utilizationClin Ther2121738510645761
   PubMed Web of Science ®Google Scholar
• FillitHM2000The pharmacoeconomics of Alzheimer’s diseaseAm J Manag Care622 SupplS113944discussion S1145–811142178
   PubMed Web of Science ®Google Scholar
• FillitHMGuttermanEMBrooksRL2000Impact of donepezil on caregiving burden for patients with Alzheimer’s diseaseInt Psychogeriatr1238940111081959
   PubMed Web of Science ®Google Scholar
• FrancoisCSintonenHSulkavaR2004Cost effectiveness of memantine in moderately severe to severe Alzheimer’s disease: A Markov Model in FinlandClin Drug Invest2437384
   PubMed Web of Science ®Google Scholar
• FratiglioniLDe RonchiDAguero-TorresH1999Worldwide prevalence and incidence of dementiaDrugs Aging153657510600044
   PubMed Web of Science ®Google Scholar
• GalaskoDRSchmittFAJinS2000Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer’s diseaseNeurobiol Aging21Suppl 1S168
   Google Scholar
• GaoSHendrieHCHallKS1998The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysisArch Gen Psychiatry55809159736007
   PubMed Web of Science ®Google Scholar
• GarfieldFBGetsiosDCaroJJ2002Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in SwedenPharmacoeconomics206293712141890
   PubMed Web of Science ®Google Scholar
• GauthierSFeldmanHHeckerJ2002Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s diseaseInt Psychogeriatr1438940412670060
   PubMed Web of Science ®Google Scholar
• GetsiosDCaroJJCaroG2001Assessment of health economics in Alzheimer’s disease (AHEAD): galantamine treatment in CanadaNeurology57972811571319
   PubMed Web of Science ®Google Scholar
• GuttermanEMMarkowitzJSLewisB1999Cost of Alzheimer’s disease and related dementia in managed-MedicareJ Am Geriatr Soc4710657110484247
   PubMed Web of Science ®Google Scholar
• HauberABGnanasakthyAMauskopfJA2000Savings in the cost of caring for patients with Alzheimer’s disease in Canada: an analysis of treatment with rivastigmineClin Ther224395110823365
   PubMed Web of Science ®Google Scholar
• HauberABGnanasakthyASnyderEH2000Potential savings in the cost of caring for Alzheimer’s disease. Treatment with rivastigminePharmacoeconomics173516010947490
   PubMed Web of Science ®Google Scholar
• HebertLEScherrPABeckettLA1995Age-specific incidence of Alzheimer’s disease in a community populationJAMA273135497715060
   PubMed Web of Science ®Google Scholar
• HebertLEScherrPABieniasJL2003Alzheimer disease in the US population: prevalence estimates using the 2000 censusArch Neurol6011192212925369
   PubMed Web of Science ®Google Scholar
• HepburnKWLewisMShermanCW2003The savvy caregiver program: developing and testing a transportable dementia family caregiver training programGerontologist439081514704391
   PubMed Web of Science ®Google Scholar
• HillJWFuttermanRMasteyV2002The effect of donepezil therapy on health costs in a Medicare managed care planManag Care Interface15637011925682
   PubMedGoogle Scholar
• HuangLFCartwrightWSHuTW1988The economic cost of senile dementia in the United States, 1985Public Health Reports103373124195
   PubMed Web of Science ®Google Scholar
• HuxMJO’BrienBJIskedjianM1998Relation between severity of Alzheimer’s disease and costs of caringCMAJ159457659757169
   PubMed Web of Science ®Google Scholar
• JonesRWMcCronePGuilhaumeC2004Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspectiveDrugs Aging216072015260515
   PubMed Web of Science ®Google Scholar
• KauferDISadikK2002Galantamine reduces caregiver time spent providing assistance to individuals with mild-to-moderate Alzheimer’s diseaseAm J Geriatr Psychiatry10suppl 1845
   Google Scholar
• KoppelR2002Alzheimer’s disease: the costs to U.S. businesses in 2002Philadelphia, PA, USAAlzheimer’s Association
   Google Scholar
• LangaKMChernewMEKabetoMU2001National estimates of the quantity and cost of informal caregiving for the elderly with dementiaJ Gen Intern Med16770811722692
   PubMed Web of Science ®Google Scholar
• LeonJNeumannP1998Alzheimer’s disease care: costs and potential savingsHealth Affairs17206169916370
   PubMed Web of Science ®Google Scholar
• LuchsingerJATangMXSheaS2003Antioxidant vitamin intake and risk of Alzheimer diseaseArch Neurol60203812580704
   PubMed Web of Science ®Google Scholar
• MarcussonJBullockRGauthierS2003Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer diseaseAlzheimer Dis Assoc Disord17Suppl 3S869114512822
   PubMed Web of Science ®Google Scholar
• MaxW1996The cost of Alzheimer’s disease. Will drug treatment ease the burden?Pharmacoeconomics951010172695
   PubMed Web of Science ®Google Scholar
• MaxWWebberPFoxP1995Alzheimer’s disease: The unpaid burden of caringJ Aging Health71799910172777
   PubMed Web of Science ®Google Scholar
• McKhannGDrachmanDFolsteinM1984Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s DiseaseNeurology34939446610841
   PubMed Web of Science ®Google Scholar
• MeekPMcKeithanKSchumockG1998Economic considerations in Alzheimer’s diseasePharmacotherapy18(2 Pt 2)6873discussion 79–829543467
   PubMed Web of Science ®Google Scholar
• Migliaccio-WalleKGetsiosDCaroJJ2003Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer’s disease in the United StatesClin Ther2518062512860500
   PubMed Web of Science ®Google Scholar
• MittelmanMSFerrisSHShulmanE1996A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trialJAMA2761725318940320
   PubMed Web of Science ®Google Scholar
• MooreMJZhuCWClippEC2001Informal costs of dementia care: estimates from the National Longitudinal Caregiver StudyJ Gerontol B Psychol Sci Soc Sci56S2192811445614
   PubMed Web of Science ®Google Scholar
• MorrisJCHeymanAMohsRC1989The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s diseaseNeurology391159652771064
   PubMed Web of Science ®Google Scholar
• MurmanDLChenQPowellMC2002The incremental direct costs associated with behavioral symptoms in ADNeurology591721912473759
   PubMed Web of Science ®Google Scholar
• MurmanDLKuoSBPowellMC2003The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodiesNeurology61944914557565
   PubMed Web of Science ®Google Scholar
• NeumannPJHermannRCKuntzKM1999Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s diseaseNeurology5211384510214734
   PubMed Web of Science ®Google Scholar
• O’BrienBJGoereeRHuxM1999Economic evaluation of donepezil for the treatment of Alzheimer’s disease in CanadaJ Am Geriatr Soc47570810323651
   PubMed Web of Science ®Google Scholar
• ParnettiLSeninUMecocciP1997Cognitive enhancement therapy for Alzheimer’s disease. The way forwardDrugs53752689129864
   PubMed Web of Science ®Google Scholar
• RaskindMAPeskindERWesselT2000Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study GroupNeurology542261810881250
   PubMed Web of Science ®Google Scholar
• ReisbergBDoodyRStofflerA2003Memantine in moderate-to-severe Alzheimer’s diseaseN Engl J Med34813334112672860
   PubMed Web of Science ®Google Scholar
• RiceDPFoxPJMaxW1993The economic burden of Alzheimer’s disease careHealth Aff (Millwood)12164768375811
   PubMed Web of Science ®Google Scholar
• RichardsSSHendrieHC1999Diagnosis, management, and treatment of Alzheimer disease: a guide for the internistArch Intern Med1597899810219924
   PubMed Web of Science ®Google Scholar
• RiveBVercellettoMDamierFD2004Memantine enhances autonomy in moderate to severe Alzheimer’s diseaseInt J Geriatr Psychiatry194586415156547
   PubMed Web of Science ®Google Scholar
• RogersRLMeyerJSMortelKF1990After reaching retirement age physical activity sustains cerebral perfusion and cognitionJ Am Geriatr Soc3812382299115
   PubMed Web of Science ®Google Scholar
• RoslerMAnandRCicin-SainA1999Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trialBMJ318633810066203
   PubMed Web of Science ®Google Scholar
• SanoMErnestoCThomasRG1997A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative StudyN Engl J Med3361216229110909
   PubMed Web of Science ®Google Scholar
• SanoMWilcockGvan BaelenB2003The effects of galantamine treatment on caregiver time in Alzheimer’s diseaseInt J Geriatr Psychiatry189425014533127
   PubMed Web of Science ®Google Scholar
• SmallGWDonohueJABrooksRL1998An economic evaluation of donepezil in the treatment of Alzheimer’s diseaseClin Ther20838509737841
   PubMed Web of Science ®Google Scholar
• SmallGWMcDonnellDDBrooksRL2002The impact of symptom severity on the cost of Alzheimer’s diseaseJ Am Geriatr Soc50321712028215
   PubMed Web of Science ®Google Scholar
• SmallGWRabinsPVBarryPP1997Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics SocietyJAMA2781363719343469
   PubMed Web of Science ®Google Scholar
• SouetreEThwaitesRMYeardleyHL1999Economic impact of Alzheimer’s disease in the United Kingdom: Cost of care and disease severity for non-institutionalised patients with Alzheimer’s diseaseBr J Psychiatry17451510211151
   PubMed Web of Science ®Google Scholar
• SternYTangMXAlbertMS1997Predicting time to nursing home care and death in individuals with Alzheimer diseaseJAMA277806129052710
   PubMed Web of Science ®Google Scholar
• StewartAPhillipsRDempseyG1998Pharmacotherapy, for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezilInt J Geriatr Psychiatry13445539695032
   PubMed Web of Science ®Google Scholar
• StommelMCollinsCEGivenBA1994The costs of family contributions to the care of persons with dementiaGerontologist341992058005492
   PubMed Web of Science ®Google Scholar
• StoneRCafferataGSanglJ1987Caregivers of the frail elderly: a national profileGerontologist27616262960595
   PubMed Web of Science ®Google Scholar
• SzafranRF2002Age-adjusted labor force participation rates, 1960–2045Monthly Labor Review1252538
   Web of Science ®Google Scholar
• TariotPNFarlowMRGrossbergGT2004Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trialJAMA2913172414734594
   PubMed Web of Science ®Google Scholar
• TariotPNSolomonPRMorrisJC2000A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study GroupNeurology5422697610881251
   PubMed Web of Science ®Google Scholar
• TaylorDSloanF2000How much do persons with Alzheimer’s disease cost MedicareJ Am Geriatr Soc486394210855599
   PubMed Web of Science ®Google Scholar
• TeriLLogsdonRYesavageJ1997Measuring behavior, mood, and psychiatric symptoms in Alzheimer diseaseAlzheimer Dis Assoc Disord11Suppl 65099437448
   PubMed Web of Science ®Google Scholar
• TeriLTruaxP1994Assessment of depression in dementia patients: association of caregiver mood with depression ratingsGerontologist3423148005496
   PubMed Web of Science ®Google Scholar
• WardACaroJJGetsiosD2003Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in the UKInt J Geriatr Psychiatry18740712891643
   PubMed Web of Science ®Google Scholar
• WilcockGHoweIColesH2003A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s diseaseDrugs Aging207778912875613
   PubMed Web of Science ®Google Scholar
• WilcockGKLilienfeldSGaensE2000Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study GroupBMJ3211445911110737
   PubMed Web of Science ®Google Scholar
• WimoALjunggrenGWinbladB1997Costs of dementia and dementia care: a reviewInt J Geriatr Psychiatry12841569283930
   PubMed Web of Science ®Google Scholar
• WimoAWinbladBEngedalK2003An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trialDement Geriatr Cogn Disord15445412457078
   PubMed Web of Science ®Google Scholar
• WimoAWinbladBGrafstromM1999The social consequences for families with Alzheimer’s disease patients: potential impact of new drug treatmentInt J Geriatr Psychiatry143384710389036
   PubMed Web of Science ®Google Scholar
• WimoAWinbladBStofflerA2003Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s diseasePharmacoeconomics213274012627986
   PubMed Web of Science ®Google Scholar
• WinbladB2002Socio-economic perspectives of dementia and cost-effectiveness of treatment7th International Geneva/Springfield Symposium on Advances in Alzheimer TherapyApril 3–6Geneva, Switzerland
   Google Scholar
• WinbladBEngedalKSoininenH2001A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate ADNeurology574899511502918
   PubMed Web of Science ®Google Scholar
• WinbladBPoritisN1999Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine)Int J Geriatr Psychiatry141354610885864
   PubMed Web of Science ®Google Scholar
• ZhuCMooreMClippE2003Dementia problem behavior and the production of informal caregiving servicesRev Econ Household15976
   Google Scholar